SPIRE: A phase Ib/randomised IIa open label clinical trial combining guadecitabine (SGI-110) with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.

Authors

Simon J. Crabb

Southampton Experimental Cancer Medicine Centre, Southampton, United Kingdom

Simon J. Crabb , Sarah Danson , James Catto , Cathy McDowell , Denise Dunkley , Robert A Huddart , Gareth Griffiths

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine chemotherapy (SPIRE): Randomized expansion phase as neoadjuvant therapy for bladder urothelial carcinoma.

First Author: Simon J. Crabb

insert_chart_outlined

Poster

2018 Genitourinary Cancers Symposium

bookmark_border

Randomized phase III study of gemcitabine and cisplatin (GC) versus dose dense methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder: The French GETUG/AFU V05 VESPER trial.

First Author: Christian Pfister

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.

First Author: Srikala S. Sridhar

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

Neoadjuvant cisplatin-based chemotherapy in patients with ureteral obstruction secondary to muscle invasive bladder cancer.

First Author: Marshall Strother